Patch/plaque mycosis-fungoides-like presentations of DUSP22-translocated T-cell lymphomas
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
The DUSP22-IRF4 gene rearrangement results in downregulation of DUSP22, a presumed tumor suppressor in T-cell lymphomagenesis. It has been described in some cases of primary cutaneous and systemic anaplastic large-cell lymphoma, lymphomatoid papulosis, and transformed mycosis fungoides. Here we describe two patients with clinical lesions resembling patch/plaque mycosis fungoides that did not meet WHO criteria for large-cell transformation on histopathology yet showed a DUSP22 translocation. One patient who had a history of systemic anaplastic large-cell lymphoma with DUSP22 translocation presented with cutaneous involvement by his systemic lymphoma along with lymphomatoid papulosis and mycosis-fungoides-like lesions, all showing an identical immunophenotype and T-cell clone. These cases expand the spectrum of DUSP22-rearranged lymphomas to include mycosis-fungoides-like presentations without large-cell transformation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Journal of cutaneous pathology - 49(2022), 3 vom: 07. März, Seite 299-305 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Runge, John S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.03.2022 Date Revised 28.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cup.14156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332391582 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332391582 | ||
| 003 | DE-627 | ||
| 005 | 20231225215458.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cup.14156 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM332391582 | ||
| 035 | |a (NLM)34699105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Runge, John S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patch/plaque mycosis-fungoides-like presentations of DUSP22-translocated T-cell lymphomas |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2022 | ||
| 500 | |a Date Revised 28.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a The DUSP22-IRF4 gene rearrangement results in downregulation of DUSP22, a presumed tumor suppressor in T-cell lymphomagenesis. It has been described in some cases of primary cutaneous and systemic anaplastic large-cell lymphoma, lymphomatoid papulosis, and transformed mycosis fungoides. Here we describe two patients with clinical lesions resembling patch/plaque mycosis fungoides that did not meet WHO criteria for large-cell transformation on histopathology yet showed a DUSP22 translocation. One patient who had a history of systemic anaplastic large-cell lymphoma with DUSP22 translocation presented with cutaneous involvement by his systemic lymphoma along with lymphomatoid papulosis and mycosis-fungoides-like lesions, all showing an identical immunophenotype and T-cell clone. These cases expand the spectrum of DUSP22-rearranged lymphomas to include mycosis-fungoides-like presentations without large-cell transformation | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a CD30 | |
| 650 | 4 | |a DUSP22 | |
| 650 | 4 | |a T-cell lymphoma | |
| 650 | 4 | |a anaplastic large-cell lymphoma | |
| 650 | 4 | |a mycosis fungoides | |
| 650 | 7 | |a Mitogen-Activated Protein Kinase Phosphatases |2 NLM | |
| 650 | 7 | |a EC 3.1.3.16 |2 NLM | |
| 650 | 7 | |a DUSP22 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.3.48 |2 NLM | |
| 650 | 7 | |a Dual-Specificity Phosphatases |2 NLM | |
| 650 | 7 | |a EC 3.1.3.48 |2 NLM | |
| 700 | 1 | |a Novice, Madison L |e verfasserin |4 aut | |
| 700 | 1 | |a Briones, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Kiyanna |e verfasserin |4 aut | |
| 700 | 1 | |a Lowe, Lori |e verfasserin |4 aut | |
| 700 | 1 | |a Boyer, Daniel F |e verfasserin |4 aut | |
| 700 | 1 | |a Wilcox, Ryan A |e verfasserin |4 aut | |
| 700 | 1 | |a Tejasvi, Trilokraj |e verfasserin |4 aut | |
| 700 | 1 | |a Hristov, Alexandra C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cutaneous pathology |d 1974 |g 49(2022), 3 vom: 07. März, Seite 299-305 |w (DE-627)NLM000403180 |x 1600-0560 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:3 |g day:07 |g month:03 |g pages:299-305 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cup.14156 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 3 |b 07 |c 03 |h 299-305 | ||